SNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
SOLIGENIX, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.34−0.01 (-2.66%)
Close on Oct 19, 2026
- Market cap
- $5.48M
- P/E (TTM)
- –
- Dividend yield
- –
SOLIGENIX, INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialized BioTherapeutics | – | $119.37K | $395.12K | $31.93K | – | $117.37K | $1.23M | $1.08M | $683.18K | – | – | – |
| Public Health Solutions [Member] | – | – | – | – | $824.27K | $2.24M | $3.40M | $4.16M | $4.75M | $10.45M | – | – |
| Public Health Solutions | – | – | $444.24K | $916.98K | $824.27K | – | – | – | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Public Health Solutions | -$88.77K | -$254.58K | -$36.53K | $26.61K | -$542.27K | – | – | – | – | – | -65.1% |
| Specialized BioTherapeutics | -$6.98M | -$4.37M | -$2.81M | -$7.61M | -$7.22M | -$13.61M | -$6.74M | -$5.44M | -$4.18M | -$3.40M | +60.0% |
| Corporate [Member] | – | – | – | – | -$5.21M | -$4.89M | -$3.96M | -$3.38M | -$3.64M | -$3.87M | – |
| Public Health Solutions [Member] | – | – | – | – | -$647.60K | -$85.42K | $153.97K | -$237.64K | $232.17K | $1.56M | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant revenue | – | $119.37K | $839.36K | $698.91K | $790.92K | $428.91K | – | – | – | – | – | – |
| Contract revenue | – | – | – | – | $33.35K | $1.93M | – | – | – | – | – | – |
| Licensing revenue | – | – | – | $250.00K | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Soligenix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.